AI-generated summary
The authors ran a split-face randomized trial in 12 patients with lichen planus pigmentosus, treating one side with four sessions of a 1064-nm picosecond laser. Eleven completed the study. The authors report no significant differences in melanin index, pigmentation severity or physician assessment between the treated and control sides, though patient satisfaction was higher on the treated side.
- Participants
- 12
- Who or what was studied
- Adults with biopsy-confirmed lichen planus pigmentosus (mean age 55 years, SD 11.1)
- Wavelengths
- 1064 nm
- Limits stated in the abstract
- The abstract notes the small sample, lack of a sham control, and that further sham-controlled trials with larger samples are needed.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Background
Lichen planus pigmentosus (LPP) is an uncommon variant of lichen planus that causes visible pigmentation and significantly impacts quality of life. Current treatments for LPP are limited, with inconsistent outcomes from topical, oral, and laser therapies. The 1064-nm picosecond laser has shown potential in managing pigmented skin disorders; however, evidence regarding its effect on LPP remains scarce.
Objectives
This study aimed to evaluate the efficacy, safety, and patient satisfaction of the 1064-nm picosecond laser in treating LPP.
Methods
The study was a randomized, split-face controlled trial. Twelve patients with biopsy-confirmed LPP were enrolled, with one side of each participant treated with four sessions of the 1064-nm picosecond laser at monthly intervals. The Modified Dermal Pigmentation Area and Severity Index (mDPASI) and melanin index (MI), assessed by three-dimensional imaging, were measured before each treatment and at 1, 3, and 6 months following the last treatment. Physician global assessment (PGA) and patient satisfaction scores were assessed at 1 and 6 months following the last treatment. Additionally, adverse events were recorded.
Results
A total of 12 patients with LPP, aged 55 ± 11.1 years, were recruited, and 11 completed the study. During the 6 months following the end of laser treatment, no significant differences were found in MI, mDPASI, or PGA between treatment and control groups. However, satisfaction scores showed a significant improvement on the treated side compared to the control. The mean overall pain score was 3.70 ± 1.72, with no major adverse events reported.
Conclusion
The 1064-nm picosecond laser demonstrated limited effectiveness in improving LPP clinical outcomes. Further studies with sham-controlled trials and larger sample sizes are needed to optimize treatment parameters and sessions, and to validate the role of the picosecond laser as a therapeutic option for LPP.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Laser, Randomized controlled trial, Melanin, Sham. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.